Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT IX in connection with the acquisition of Parexel
Mandate

Vinge advises EQT IX in connection with the acquisition of Parexel

December 14, 2021 EU, Competition and Regulatory

Vinge has advised EQT IX on the merger control aspects of EQT IX’s and Goldman Sachs Asset Management’s acquisition of Parexel from Pamplona Capital Management for USD 8.5 billion.

Parexel carries out biopharmaceutical outsourcing services providing a comprehensive suite of Phase I to IV solutions to the world’s biopharmaceutical companies. The acquisition was notified to a number of competition authorities worldwide including to the European Commission. Vinge’s team consisted primarily of Emma Johansson, Johan Wahlbom, Victoria Fredén and Jesper Ekman.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026

Vinge has advised Resurs in connection with its strategic partnership with Kustom

 Vinge has advised Resurs in connection with its strategic partnership with Kustom (formerly Klarna Checkout), a fast-growing player in the digital commerce sector. The partnership enables Resurs to accelerate its strategic development by offering a check-out solution to its merchants, built on Kustom’s market-leading infrastructure.
March 25, 2026